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ARTICLE OPEN
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Transduction of muscle sympathetic nerve activity (MSNA) into vascular tone varies with age and sex. Older normotensive men
have reduced sympathetic transduction so that a given level of MSNA causes less arteriole vasoconstriction. Whether sympathetic
transduction is altered in hypertension (HTN) is not known. We investigated whether sympathetic transduction is impaired in
untreated hypertensive men compared to normotensive controls. Eight untreated hypertensive men and 10 normotensive men
(age 50 ± 15 years vs. 45 ± 12 years (mean ± SD); p= 0.19, body mass index (BMI) 24.7 ± 2.7 kg/m2 vs. 26.0 ± 4.2 kg/m2; p= 0.21)
were recruited. MSNA was recorded from the peroneal nerve using microneurography; beat-to-beat blood pressure (BP; Finapres)
and heart rate (ECG) were recorded simultaneously at rest for 10min. Sympathetic-transduction was quantified using a previously
described method. The relationship between MSNA burst area and subsequent diastolic BP was measured for each participant with
the slope of the regression indicating sympathetic transduction. MSNA was higher in the hypertensive group compared to
normotensives (73 ± 17 bursts/100 heartbeats vs. 49 ± 19 bursts/100 heart bursts; p= 0.007). Sympathetic-transduction was lower
in the hypertensive versus normotensive group (0.04%/mmHg/s vs. 0.11%/mmHg/s, respectively; R= 0.622; p= 0.006). In summary,
hypertensive men had lower sympathetic transduction compared to normotensive individuals suggesting that higher levels of
MSNA are needed to cause the same level of vasoconstrictor tone.
Journal of Human Hypertension; https://doi.org/10.1038/s41371-021-00578-5
INTRODUCTION
The arrival of a sympathetic nerve action potential to the
neurovascular junction initiates an intracellular cascade resulting
in the release of noradrenaline and other co-transmitters [1].
Abluminal receptors on the vascular smooth muscle transduce this
signal, usually resulting in vasoconstriction through the activation
of adrenoreceptors [2]. This is a key mechanism by which the
sympathetic nervous system (SNS) regulates arterial tone and
hence arterial pressure in humans.
How effectively the vasculature can react to sympathetic neural
activity (SNA) is dependent on the various mechanisms that
transduce the signal from the postganglionic nerve terminals to
the contractile responses of the vasculature. Other vasoactive
molecules such as endothelin, purines, or nitric oxide can also
modulate the efficacy of the SNA on vascular tone [3, 4]. The
transduction of SNA into vascular tone is a major contributor to
the ability of the SNS to control blood pressure (BP) [5, 6]. This
process is sensitive to numerous other modulatory influences,
such as how much neurotransmitter is released, the latency of
neurotransmitter clearance from the synaptic cleft, and second
messenger amplification within the vasculature [7]. The relative
densities of α- and β- adrenoreceptors within the target area of
the sympathetic bouton can result in vasoconstriction or
vasodilatation depending on local receptor proportions [7]. Using
different methods there have been multiple attempts to quantify
the transduction of SNA over the last few decades [8–10]. For
example, using an isometric handgrip to elevate BP and SNA from
baseline [11]. Our group has created a novel analytical technique
of measuring sympathetic transduction and has subsequently
identified differences in the transduction of the SNA signal
between both young and old individuals of both sexes [12].
In this study, we aimed to identify differences in sympathetic-
transduction between normotensive men and untreated hyper-
tensive men at rest. In short, transduction was quantified by
measuring muscle sympathetic nerve activity (MSNA) and obser-
ving the subsequent effect on diastolic blood pressure (DBP). The
method of measuring sympathetic transduction in this study has
been previously described [12]. Surprisingly, there have been no
studies to date that have examined differences in sympathetic
transduction between normotensive and hypertensive individuals.
We hypothesized that sympathetic transduction would be higher
in untreated hypertensive individuals compared to normotensive
individuals. Identifying differences in transduction could lead to a
greater understanding of the SNS in hypertension and provide a
new tool to predict the efficacy of current treatment options.
METHODS
Participants
Following approval by the National Health Service ethics committee (11/
SW/0207) and local R&D approval, we recruited 10 normotensive men and
8 untreated hypertensive men between the ages of 25 and 70 years. Men
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were recruited for this study because the balance between cardiac output,
total peripheral resistance, and SNA is well understood and due to the fact
that sympathetic transduction varies significantly in women [9]. All
participants that took part in this study gave informed written consent
to participate. The study was completed in full accordance with the
Declaration of Helsinki.
Untreated hypertensive patients were defined as patients who are not
currently taking any anti-hypertensive medications, an office BP recording
of ≥140/90mmHg, and ambulatory daytime BP ≥ 135/85mmHg [13].
Normotensive patients were defined as having an average systolic blood
pressure (SBP) during the daytime of <135mmHg and DBP < 85mmHg
whilst not taking any medications, including antihypertensive agents. All
the normotensive participants were healthy with no diagnosis of
cardiovascular or pulmonary disease.
Participants were excluded from the study if they had any diagnosed
cardiovascular disorders (excluding hypertension), such as cardiac
electrical conduction abnormalities, heart failure or respiratory diseases
such as chronic obstructive pulmonary disease (COPD). Other exclusion
criteria included whether participants were currently suffering from any
major illnesses such as cancer or inflammatory diseases, were currently
taking steroids or nitrates, had a febrile illness within two weeks of the
study date or had a body mass index (BMI) > 35 kg/m2. Intravenous drug
users and individuals consuming more than 28 units of alcohol per week
were also excluded.
Screening
Participants were invited for a screening visit to establish suitability for the
study. Clinic BP was recorded using an automated oscillatory sphygmo-
manometer (Omron, M6, Netherlands) while seated and in line with the
2018 European guidelines for BP measurement [13]. Urinalysis was used to
screen for the presence of glycosuria, haematuria, and proteinuria, which
might suggest underlying renal disease or diabetes. A 12-lead electro-
cardiogram (ECG) was performed and checked by a cardiologist to rule out
any cardiac conduction abnormalities or ischaemia. If the study criteria
were met, participants were sent home with an ambulatory BP monitor
(ABPM) to be worn for 24 h (Spacelabs, 90217A, USA). The device inflated
every 30min during waking hours and every hour during sleeping hours
[13]. Indexes of daytime blood pressure variability (BPV) were calculated as
the SD of the daytime SBP and DBP, and the average real variability (ARV)
of the SBP and DBP. This measure is the average of the absolute
consecutive BP readings and is thought to be a better index of BPV than
the SD because the SD reflects the dispersion of the BP reading around the
mean, whereas the ARV reflects the actual variability between consecutive
BP measurements [14]. ARV is also thought to be a better predictor of
cardiovascular risk in people with hypertension versus the SD of daytime
BP [15].
Measurements
All of the measurements in this study took place in a clinical research unit
at the Clinical Research and Imaging Centre (CRiC), Bristol, UK. The ambient
temperature in the laboratory was controlled at 21 °C. The participants
were asked to rest in the supine position at 30°. They were fitted with a
continuous 3-lead ECG (BioAmp, Ad instruments) to measure heart rate
and rhythm.
BP was measured continuously using a Finapres (Finometer® PRO, FMS)
non-invasive BP monitor. The recording of BP using the Finapres was
calibrated by using an automated sphygmomanometer on the same arm.
Multi-unit MSNA was recorded from the right peroneal nerve, laterally at
the level of the head of the fibular as we have performed previously [9, 12].
The electrode in the nerve was aimed to target muscle sympathetic
fascicles. A muscle sympathetic fascicle was identified when taps on the
tibialis anterior muscle belly or passive muscle stretch evoked mechan-
oreceptive impulses, and no afferent neural response was evoked by skin
or startle stimuli [16]. The recorded signal was amplified 80,000-fold, band-
pass filtered (700–2000 Hz), rectified, and integrated (resistance-capaci-
tance integrator circuit time constant 0.1 s) by a nerve traffic analyser.
Data analysis
Data were sampled at 1000 Hz using a data acquisition system (LabChart,
AD instruments) and stored on a laboratory computer (password
protected) for later analysis. MSNA, heart rate, mean arterial pressure
(MAP), SBP, and DBP were assessed as an average from the 10min
baseline. MSNA is expressed as burst incidence (bursts/100 heartbeats),
burst frequency (bursts/min) and total activity (burst frequency multiplied
by mean burst area; arbitrary units (AU)/min). The transduction was
measured by quantifying the relationship between the MSNA burst area
and subsequent DBP readings [12]. The individual bursts of MSNA activity
were marked in an analysis suite (Spike 2 (v7), CED, UK) for the peak, start
and end of each burst. Any drift present in the MSNA readings was
removed by using a DC filter and the MSNA signal was normalized. For
each participant, MSNA bursts were calibrated as a percentage with the
amplitude of the largest burst represented as 100% and an area of baseline
with no MSNA burst as 0%. We took each DBP reading and summed the
MSNA burst area within two cardiac-cycle that preceded this DBP reading
at a fixed lag. We search backwards from the DBP to allow us to include
periods where there are no bursts in the neurogram. This fixed lag was
calculated for each participant by plotting a waveform average (signal
average) of MSNA events and DBP versus time and reading for the peak.
The average lag (or delay) between a burst of SNA and the subsequent
peak rise in DBP was 6–8 cardiac cycles. In four patients, it this was not
possible to calculate the ‘lag’ as there was no clear peak in the rise of their
BP after a burst had occurred, thus a fixed lag of 6–8 cardiac cycles was
used as this was shown to be the average for participants. A window of
two cardiac cycles at fixed lag for each individual was used to measure the
area under the curve in the integrated MSNA neurogram (i.e., area under
the curve within the 2 heartbeats). This was associated with the
subsequent DBP (e.g., 6–8 cardiac cycles proceeding these heartbeats).
We then plotted DBP vs. MSNA at the calculated lag to produce an XY
scatter plot. The MSNA burst area was further binned into 1%/s bins with
its associated DBP reading, averaged and put through a weighted linear
regression. The slope of the regression was quantified as the MSNA
transduction efficacy as previously described [12].
Time, frequency and non-linear indexes of short term heart rate
variability (HRV) were measured using the LabChart HRV module (AD
instruments, version 8) in accordance with the guidelines from the Task
Force of the European Society of Cardiology and the North American
Society for pacing electrophysiology [17]. Time-domain indexes included
the root mean square of successive RR interval differences (rMSSD), the
standard deviation of RR interval (SDRR), percentage of successive RR
interval differences longer than 50m (pRR50%) and the ratio of SDRR and
the mean RR interval (CVRR). Frequency domain parameters of R–R
intervals (via fast Fourier transform) included total power, very low
frequency (VLF; 0–0.04 Hz), low frequency (LF; 0.04–0.15 Hz) and high
frequency (HF; 0.15–0.45 Hz). Total power, VLF, LF and HF parameters were
expressed in absolute values (ms2) and LF, HF and LF/HF ratios were also
expressed as normalised units. Non-linear measures of HRV included the
SD of the Poincare plot (SD1, SD2 and SD1/SD2 ratio). A Poincare plot was
produced by plotting the RR interval against the subsequent RR interval.
The SD1 is related to fast beat-to-beat variability whereas SD2 is linked to
long-term RR interval variability and is influenced by both sympathetic and
parasympathetic components. Indexes of parasympathetic function are
thought to be rMSSD, SDRR, pNN50% and HF fluctuations in heart rate (in
the 0.15–0.45 Hz power band). There is uncertainty regarding exactly what
the LF component and LF/HF ratio represent physiologically [18]; with
some suggesting they evaluate a sympathetic function, however, this has
been debated in humans [19].
Finally, we calculated spontaneous indexes of sympathetic and
cardiovagal baroreflex sensitivity (BRS). Spontaneous sympathetic barore-
flex sensitivity (sBRS) was calculated by associating spontaneous fluctua-
tions in DBP to the occurrence of bursts of MSNA. The analysis that we
used has been termed “threshold analysis” and has been described in
detail [20, 21]. In brief, DBP for each cardiac cycle (recorded during the
baseline period) were grouped into BP bins of 1 mmHg. The % of
heartbeats associated with a burst in each of these BP bins was calculated
and associated with the mean DBP in the corresponding bin. The slope of
the relationship between the mean DBP and mean MSNA for each DBP bin
was calculated using linear regression. The slope of this relationship has
been previously shown to agree with the BRS calculated during a modified
Oxford baroreflex test [20]. The spontaneous cardiovagal BRS (cBRS) was
assessed using the sequence technique [22]. Briefly, sequences of three or
more successive heartbeats in which there were simultaneous increases or
decreases in SBP and RR interval were selected using commercially
available software (CardioSeries, version 2.4, Ribeirao Preto, SP, Brazil).
Linear regression was applied to each of the sequences and an average
regression slope was calculated for the sequences detected during each
recording period. This slope represents the spontaneous cardiac BRS. Data
regarding the slope of the cardiac baroreflex were averaged across falling
and rising SBP.
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Data were statistically analysed using MatLab (The MathWorks, Natick, MA,
USA). Data were checked for normality using the Shapiro–Wilk test and a
two-tailed Student’s T test corrected for unequal variance was used to
assess for differences in means. Pearson’s correlation coefficient was used
to test for relationships between variables. Data are presented as mean ±
standard deviation (SD). Alpha was set at 0.05.
RESULTS
Participant demographics
Table 1 shows participant demographics. BMI and age were similar
between the hypertensive and normotensive groups. Daytime
ABPM showed that DBP, SBP and MAP were higher in the
untreated hypertensive men compared to normotensive controls.
There was no difference in the BPV based on the SD of daytime
SBP and DBP. Based on the ARV index of BPV, the hypertensive
group had higher variability in the SBP vs the normotensives, but
no difference in DBP. Clinic SBP, DBP and MAP were also higher in
the hypertensive versus the control group. Ambulatory and clinic
HR were similar between groups. In both groups, there was a
significant correlation between age and MSNA as seen in Fig. 1
(bursts/100 heartbeats) (NTN r= 0.61; P= 0.0072, uHTN r= 0.52;
p= 0.042).
MSNA and spontaneous BRS
MSNA was 48% higher in the untreated hypertensive group
compared to the normotensive men (Table 1 for burst/100
Table 1. Demographics and baseline neural-haemodynamic variables in men with untreated hypertension and normotension.
Normotensive men Untreated hypertensive men P-Value
Age (years) 45 ± 12 50 ± 15 0.19
Height (m) 1.80 ± 0.07 1.76 ± 0.04 0.11
Weight (kg) 80.2 ± 10.3 81.4 ± 14.4 0.42
BMI (kg/m2) 24.7 ± 2.7 26.0 ± 4.2 0.21
Daytime ABPM
SBP (mmHg) 124 ± 8 151 ± 25 0.003
DBP (mmHg) 80 ± 6 94 ± 18 0.019
MAP (mmHg) 95 ± 6 113 ± 20 0.008
HR (beats/min) 78 ± 10 74 ± 7 0.24
ABPM BPV
SBP SD (mmHg) 13.3 ± 3.5 13.4 ± 4.6 0.75
DBP SD (mmHg) 10.0 ± 3.0 9.8 ± 1.3 0.83
SBP ARV (mmHg) 8.1 ± 1.1 12.3 ± 2.4 0.01
DBP ARV (mmHg) 7.6 ± 2.8 9.0 ± 1.7 0.28
Clinic BP
SBP (mmHg) 125 ± 8 165 ± 32 <0.001
DBP (mmHg) 80 ± 8 98 ± 18 0.009
MAP (mmHg) 95 ± 9 120 ± 23 0.002
HR (beats/min) 66 ± 16 62 ± 7 0.22
MSNA (Bursts/100 Heartbeats) 49 ± 19 73 ± 17 0.007
MSNA (Bursts/min) 31 ± 7 45 ± 11 0.002
Total MSNA activity (AU/min) 372 ± 26 648 ± 35 0.001
sBRS (%/mmHg) −3.08 ± 2.11 −2.50 ± 1.89 0.850
cBRS (ms/mmHg)
All sequences 17.6 ± 6.2 16.8 ± 4.7 0.81
Up sequences 18.0 ± 6.3 15.22 ± 3.9 0.40
Down sequences 14.9 ± 4.3 19.5 ± 7.1 0.24
Data are shown as mean ± standard deviation. Data analysed using Student’s T Test.
BMI body mass index, ABPM ambulatory blood pressure monitoring, MAP mean arterial pressure, HR heart rate, SBP systolic blood pressure, DBP diastolic blood
pressure, BPV blood pressure variability, SD standard deviation, ARV average real variability, MSNA muscle sympathetic nerve activity, sBRS sympathetic
baroreflex sensitivity, cBRS cardiovagal BRS.
Fig. 1 Correlation of age versus resting muscle sympathetic
activity (MSNA), and sympathetic-vascular transduction. MSNA
versus age (NTN; r= 0.61; p= 0.0072) or untreated hypertension
(uHTN; r= 0.52; p= 0.042). There is no difference between the
slopes of the correlation between age and MSNA (p= 0.52).
M.D. Kobetic et al.
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heartbeats and bursts/min). There was a correlation between
resting MSNA (bursts/100 heartbeats) and ambulatory daytime
SBP (r= 0.54, p= 0.022) and MAP (r= 0.45, p= 0.048) when the
groups were combined. There was no relationship between MSNA
and ambulatory daytime DBP (r= 0.37, p= 0.013). MSNA
expressed as bursts/min was correlated to daytime ambulatory
SBP (r= 0.66, p= 0.003), DBP (r= 0.50, p= 0.04) and MAP (r=
0.58, p= 0.01). MSNA (bursts/100 heartbeats) was only correlated
with clinic SBP (r= 0.44, p= 0.037) and not to clinic DBP (r= 0.18,
p= 0.18) and MAP (r= 0.28, p= 0.26). MSNA (bursts/min) was
significantly correlated to clinic SBP (r= 0.57; p= 0.01) and clinic
MAP (r= 0.49; p= 0.04) but was not significantly correlated to
clinic DBP (r= 0.40; p= 0.10). There were no differences in sBRS
and cBRS between groups (Table 1).
HRV
There were no differences in time- and frequency-domain or non-
linear measures of HRV between hypertensive and normotensive
groups (Table 2). Measures of HRV did however correlate with age
(Table 3; SDNN, CVNN, total power (ms), LF (ms), HF (ms) and SD2).
There was no correlation of HRV parameters to ambulatory
daytime SBP or sympathetic- transduction (Table 3). Interestingly,
there was a moderate correlation (r= 0.49) of sympathetic-
transduction to LF HRV but did not reach p ≤ 0.05 (p= 0.056).
Sympathetic-transduction
An example of the linear regressions used to calculate sympa-
thetic transduction is shown in Fig. 2, in a hypertensive and
normotensive participant. After applying our method of quantify-
ing sympathetic-transduction from MSNA and subsequent DBP
readings, transduction was found to be lower in the hypertensive
group compared to our normotensive controls (0.04 ± 0.05%/
mmHg/s vs. 0.11 ± 0.04%/mmHg/s; p= 0.003; Fig. 3).
Sympathetic-transduction vs. MSNA, age and BP
Transduction was inversely correlated with increased resting
MSNA (bursts per 100 heartbeats) in both groups individually as
well as in the entire dataset (Fig. 4; r= 0.62; p= 0.006). The
correlation was the same when MSNA measured in bursts per
minute was used (r= 0.62; p= 0.006). Combining the data sets, we
found that sympathetic-transduction was positively correlated
with age (r= 0.67, p= 0.002), but not to BMI (r= 0.20, p= 0.42).
When groups were considered separately, there was a correlation
between age and transduction in both groups (NTN r= 0.44; p=
0.038, uHTN r= 0.56; p= 0.03). There was no difference between
the slopes of the correlation between age and MSNA (p= 0.52), or
between age and transduction (p= 0.99; Fig. 4).
The daytime SBP (r=−0.69; p= 0.002) and DBP (r=−0.68, p=
0.002) were inversely correlated with the level of sympathetic-
transduction so that higher daytime SBP and DBP were linked to
lower levels of sympathetic-transduction (or vice-versa). We also
found that there was a strong inverse correlation between the ARV
index of daytime SBP variability and sympathetic-transduction
(r=−0.75, p= 0.001) so that higher transduction was linked to
lower daytime BPV (or vice-versa). The ARV of DBP (r=−0.43, p=
0.075) or the SD of the SBP (r=−0.42, p= 0.091) and DBP (r=
−0.29, p= 0.243) were not correlated with the level of
sympathetic-transduction.
DISCUSSION
The main finding of this study is that men with untreated
hypertension have a lower sympathetic transduction compared to
normotensive men of the same age. The level of sympathetic
transduction was inversely linked to the level of resting MSNA.
MSNA
These results show that untreated hypertensive men have a
significantly higher MSNA compared to normotensive men,
supporting previous studies [9, 23–25]. The elevated MSNA is
thought to be a factor involved in the development and
maintenance of hypertension in humans [26]. Here we show that
resting MSNA is positively related to daytime ABPM so that higher
MSNA is associated with higher daytime BP. This supports
previous data showing that MSNA is linked to the level of resting
BP in middle-aged men and women [27]. MSNA was only
moderately correlated with clinic SBP, but not to clinic DBP and
MAP, suggesting that resting MSNA is better at predicting BP out
of the clinic. The mechanism(s) underlying elevated sympathetic
tone in people with hypertension are multi-factorial, but include
activation of the renin-angiotensin-system [28], peripheral che-
moreflex involvement [29], baroreflex dysfunction [30], chronic
stress [31], poor organ perfusion [32], obesity as well as insulin and
leptin levels [26, 33].
Neurovascular transduction
We used a previously validated measure of sympathetic transduc-
tion [12] to estimate whether sympathetic- transduction is altered
in men with untreated hypertension. This measure of transduction
provides an estimate of how responsive the DBP is to beat
changes in the MSNA area. Thus, the data suggest that the
responsiveness of the DBP to a given increase in MSNA is lower in
men with hypertension versus normotensive men. The results
infer that in men with hypertension, a given increase in the level
of MSNA causes less vasoconstriction versus that in men with
normotension. Potentially, men with hypertension need a larger
increase in MSNA to achieve the same change in DBP, but this
needs to be assessed using interventions that increase MSNA. The
data also suggest that men with untreated hypertension would
also need a greater change in MSNA versus normotensive men to
achieve the same fall in DBP. For example, the average
sympathetic transduction slopes indicate that to achieve a





rMSSD (ms) 40.91 ± 15.4 34.7 ± 21.7 0.51
SDRR (ms) 54.1 ± 11.4 48.8 ± 22.7 0.85
pRR50 (%) 21.0 ± 17.8 14.0 ± 19.8 0.53
CVRR 0.06 ± 0.02 0.05 ± 0.02 0.52
Total power
(ms2)
3180 ± 1404 2402 ± 2122 0.40
VLF power
(ms2)
1088 ± 797 926 ± 689 0.67
LF power
(ms2)
1168 ± 1020 747 ± 959 0.41
HF power
(ms2)
885 ± 1125 695 ± 952 0.72
LF/HF 2.65 ± 2.74 1.91 ± 1.44 0.51
LF (nu) 56.1 ± 27.3 59.3 ± 16.0 0.78
HF (nu) 41.5 ± 25.4 39.4 ± 13.7 0.84
SD1 (ms) 29.0 ± 10.9 24.5 ± 15.3 0.51
SD2 (ms) 70.1 ± 15.6 64.1 ± 29.0 0.61
SD1/SD2 0.42 ± 0.16 0.37 ± 0.12 0.45
Values are mean ± SD. P-value from unpaired Students t-test.
rMSSD root mean square of successive RR interval differences, SDRR
standard deviation of RR interval, pRR50 percentage of successive RR
interval differences longer than 50ms, CVRR ratio of SDRR and the mean RR
interval, VLF very low frequency (0–0.04 Hz), LF low frequency
(0.04–0.15 Hz), HF high frequency (0.15–0.45 Hz), SD standard deviation of
the Poincare plot.
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1mmHg fall (or rise) in DBP, the area of the MSNA burst would
need to decrease (or rise) by 8.3%/s in the normotensive men and
25%/s in the untreated hypertensive men. This assumes that the
regression curve is linear (see Fig. 2 for example regressions).
However, if we were to test across a whole range of MSNA and
DBP, it is likely that the regression is sigmoidal.
There are several potential mechanisms that may explain the
lower sympathetic transduction in patients with untreated
hypertension. First, hypertension is associated with higher
vasoconstrictor tone and total peripheral resistance [7]. It is
possible that hypertensive patients have a tonic contraction of the
smooth muscle which is close to the saturation point (i.e., no more
force can be generated by the muscle by further depolarization),
therefore the smooth muscle cannot contract further to increased
sympathetic stimuli. Second, the vessel remodelling that occurs in
hypertension [34] may mean that the vessels are less able to
constrict in response to sympathetic stimuli. For example,
fundamental changes that occur within smooth muscle cells in
hypertension, such as increased collagen, may alter the mechan-
ical function of the cell [35] reducing the degree of absolute
contractility. Third, α-adrenoreceptor desensitisation due to
Table 3. Pearson correlation coefficients to measure the relationship of age, SBP (ambulatory) and sympathetic transduction to heart rate variability
parameters and sympathetic (sBRS) and cardiovagal (cvBRS) baroreflex sensitivity in all participants (hypertension and normotension grouped
together).
Age (p-value) Sympathetic transduction (p-value) Daytime ambulatory SBP (p-value)
rMSSD (ms) −0.46 (p= 0.075) 0.10 (p= 0.685) −0.19 (p= 0.487)
SDNN (ms) −0.66 (p= 0.005) 0.34 (p= 0.200) −0.29 (p= 0.285)
pNN50 (%) −0.42 (p= 0.105) 0.11 (p= 0.684) −0.26 (p= 0.324)
CVRR −0.72 (p= 0.002) 0.46 (p= 0.075) −0.24 (p= 0.378)
Total power (ms2) −0.67 (p= 0.001) 0.41 (p= 0.109) −0.35 (p= 0.183)
VLF power (ms2) −0.07 (p= 0.803) 0.16 (p= 0.545) −0.22 (p= 0.424)
LF power (ms2) −0.64 (p= 0.008) 0.49 (p= 0.056) −0.21 (p= 0.446)
HF power (ms2) −0.49 (p= 0.050) 0.14 (p= 0.594) −0.25 (p= 0.349)
LF/HF −0.16 (p= 0.562) 0.45 (p= 0.091) −0.09 (p= 0.734)
LF (nu) −0.01 (p= 0.803) 0.29 (p= 0.270) 0.09 (p= 0.727)
HF (nu) 0.07 (p= 0.794) −0.30 (p= 0.262) −0.07 (p= 0.782)
SD1 (ms) −0.46 (p= 0.075) 0.10 (p= 0.712) −0.29 (p= 0.487)
SD2 (ms) −0.68 (p= 0.004) 0.38 (p= 0.149) −0.29 (p= 0.276)
SD1/SD2 0.07 (p= 0.789) −0.26 (p= 0.363) 0.06 (p= 0.577)
sBRS (%/mmHg) 0.35 (p= 0.211) −0.29 (p= 0.331) 0.25 (p= 0.371)
cvBRS (ms/mmHg) 0.02 (p= 0.811) −0.17 (p= 0.512) −0.26 (p= 0.351)
See Table 2 for abbreviations. Values are Pearson’s r and respective p-value.
Significant correlation coefficients are in bold.
Fig. 2 Example of data used to calculate sympathetic-vascular
transduction in a hypertensive (HTN) and normotensive (NTN)
male. For each DBP the MSNA burst area was measured (area under
the curve) in a two cardiac cycle window at a fixed lag of 6–8 cardiac
cycles preceding the DBP for both participants. This ‘window’ was
moved across the whole baseline file, associating each DBP with an
MSNA burst area. These data were represented as a scatter plot.
MSNA burst area was then binned into 1%/s bins, and the
corresponding DBP (mean ± SD) plotted. A weighted linear regres-
sion was then fitted to these data, the slope of which gave our
measurement of transduction (units of mmHg (%/s)). MSNA muscle
sympathetic nerve activity, DBP diastolic blood pressure.
Fig. 3 Sympathetic-vascular transduction in men with normoten-
sion (NTN) and untreated hypertension (uHTN). Mean ± standard
deviation, **p= 0.0083.
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chronic exposure to noradrenaline may occur [25]. This could
involve uncoupling of the receptor from the G protein complex
and the internalisation of the receptor. Along these lines, we show
that the estimate of sympathetic-transduction is inversely linked
to the level of MSNA. However, previous reports have shown that
forearm vascular responses to noradrenaline are similar to
normotensives in treated-hypertensive [36] as well as patients
with hypertension who discontinued medication for 2 weeks
before assessment [37], suggesting that vasoconstrictor responses
to exogenous α-adrenergic agonists are similar in hypertension.
However, other studies indicate that the response of forearm
vascular resistance to α-adrenergic receptor agonist infusion is
elevated [38, 39] or not changed in people with hypertension [40].
The disparity between these studies and ours may be explained
by the techniques used. Here we show that dynamic responses to
SNA may be blunted in hypertension, whereas intra-arterial
infusion of an agonist and assessment of responses are completed
over a longer time period and reflect ‘steady state’ responses of
the vessels. In addition, the studies using exogenous administra-
tion of adrenergic agonists only consider post-synaptic mechan-
isms and do not allow an assessment of alterations in pre-synaptic
modulation via autoreceptors on sympathetic fibres. Further
studies will be needed to elucidate the true underlying mechan-
ism for our novel observations.
Finally, despite a lower measure of sympathetic-transduction in
hypertension, MSNA was directly linked to the level of ambulatory
BP. Potentially, the overall higher level of MSNA supports a higher
tonic vasoconstrictor tone despite the lower sympathetic
transduction, which contributes to higher BP in hypertension. It
is also possible that the tonically higher MSNA in hypertension
contributes to the development of vascular stiffness (via
remodelling of vascular smooth muscles cells [34]) so that high
MSNA supports a higher BP.
Limitations
In this study, 8 uncontrolled hypertensive men and 10 normo-
tensive men were investigated. This is a small sample size. Our
study sample was only in men, as sympathetic transduction has
been shown to vary significantly in women [12]. Our sample was
also not matched for age (on a case-control basis), however, as the
mean age of both groups were similar it is likely that this is only of
minor importance. Another potential limitation is that this study
was unmatched for race or ethnic group, as it has been shown
that vascular adrenergic constriction is increased in people with
African Caribbean ethnicity [41]. Finally, we were unable to
measure cardiac output during this study using valid techniques,
thus we do not have measures of total peripheral resistance. Using
changes in resistance in response to MSNA would have provided a
further measure of sympathetic transduction into vasomotor tone.
Implications
Hypertension has been shown to cost the NHS in excess of £2
billion per year. It is estimated that currently, 33% of adults
worldwide have high BP [42]. Further to this, 60% of people being
currently being treated for hypertension have BP controlled to
within the normal range [42]. As a risk factor with such a profound
burden on global health, increasing our knowledge and under-
standing of the pathogenesis of hypertension is vitally important.
Our study has shown that untreated hypertensive men have lower
sympathetic-vascular transduction than normotensive men. Thus,
although MSNA is high, the vasoconstrictor effects of further
increases (or dilator effects of decreases) in MSNA are blunted in
untreated hypertensive males. This may offer a protective
mechanism of preserving the vasculature against further increases
in MSNA. However, it also suggests that when the MSNA reduces,
there may be less of a decrease in DBP of vasoconstrictor tone.
These findings also highlight the fact that when considering the
role of the SNS in hypertension, more than just the level of SNA
should be taken into account [43]. A richer understanding of how
sympathetic-vascular transduction is implicated in hypertension
may help us target anti-hypertensive medications more accurately
as well as tailor our existing therapies more effectively. Future
studies could examine how different classes of anti-hypertensive
treatments affect sympathetic transduction both acutely but also
chronically, especially given that many treatments do not reduce
SNA despite a decrease in BP.
Summary
What is known about topic
● The transduction of sympathetic nerve activity (SNA) into
vascular tone is a major contributor to the sympathetic control
blood pressure (BP).
● Using different methods there have been multiple attempts to
quantify the transduction of SNA over the last few decades.
● Our group created a novel analytical technique of measuring
sympathetic transduction, which confirmed differences in the
transduction of the SNA into vascular tone between men
and women.
● Since the vasoconstrictor response to a given level of SNA
could impact BP control it is important to understand whether
there is a difference in sympathetic transduction between
people with hypertension versus normotensive controls.
Fig. 4 Correlations of sympathetic transduction to resting MSNA
levels and age in both normotensive and untreated hypertensive
men. A correlation of sympathetic-vascular transduction to resting
muscle sympathetic activity (MSNA) in men with normotension
(NTN; r= 0.48; p= 0.16) or untreated hypertension (uHTN; r= 0.33;
p= 0.23). When the groups were combined there was an inverse
correlation between the two variables (r=−0.622; p= 0.006).
B Sympathetic transduction versus age (NTN; r= 0.44; p= 0.038)
or untreated hypertension (uHTN; r= 0.56; p= 0.03). There is no
difference between the slopes of the correlation between age and
sympathetic-vascular transduction (p= 0.99).
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What this study adds
● This study has examined differences in sympathetic transduc-
tion between normotensive and hypertensive males.
● The main finding of this study is that men with untreated
hypertension have lower sympathetic transduction compared
to normotensive men of the same age.
● The level of sympathetic transduction was inversely linked to
the level of resting muscle sympathetic nerve activity (MSNA),
suggesting that desensitization of the vasculature to MSNA is
linked to elevated adrenergic stimuli.
● These findings suggest that men with hypertension need a
higher level of SNA to cause increases in BP. Conversely, the
data show that they also need a larger reduction in SNA to
cause the same fall in BP.
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